08:00 , Nov 24, 2003 |  BC Week In Review  |  Clinical News

DCF 987: Phase II

In a double-blind, Canadian Phase II trial in 60 patients, 1000 mg DCF 987-treated patients had a mean FEV1 improvement of 2.55%, 500 mg DCF 987 patients had a 0.55% improvement, and placebo patients had...
07:00 , Aug 11, 2003 |  BC Week In Review  |  Clinical News

DCF 987: Phase II

BCY completed enrollment in a Canadian Phase II trial of DCF 987. The double-blind, placebo-controlled study is designed to assess the effect of both 500 and 1000 mg twice-daily doses of DCF 987 on pulmonary...
07:00 , Aug 7, 2003 |  BC Extra  |  Clinical News

BCY completes Phase II cystic fibrosis trial

BCY LifeSciences (TSE:BCY) completed enrollment in a Canadian Phase II trial of DCF 987 inhaled mucolytic dextran agent to treat cystic fibrosis (CF). The double-blind, placebo-controlled study is designed to assess the affect of both...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Company News

BCY LifeSciences Inc. board of directors update

BCY LifeSciences Inc. (CDNX:BCY), Toronto, Ontario   Business: Pulmonary   Appointed: Diane Kalina, VP of licensing at BioCatalyst Yorkton; she replaces Brad Thompson, who departed  ...
07:00 , Apr 7, 2003 |  BC Week In Review  |  Clinical News

DCF 987 inhaled mucolytic dextran agent regulatory update

The FDA granted Orphan Drug designation for DCF 987 to treat cystic fibrosis (CF). The compound is in Phase II testing. BCY LifeSciences Inc. (CDNX:BCY), Toronto, Ontario   Product: DCF 987 inhaled mucolytic dextran agent...
08:00 , Dec 23, 2002 |  BC Week In Review  |  Clinical News

DCF 987: Phase II

BCY started a Canadian Phase II trial of DCF 987 in 75 patients. BCY LifeSciences Inc. (CDNX:BCY), Toronto, Ontario   Product: DCF 987   Business: Pulmonary   Therapeutic category: Immune stimulation   Target: Macrophages  ...
07:00 , Oct 14, 2002 |  BC Week In Review  |  Company News

BCY LifeSciences Inc., Biovail deal

BCY granted BVF an option to evaluate and negotiate future licenses for products belonging to BCY, including lead compound DCF 987, which is an inhaled mucolytic dextran agent expected to enter Phase II cystic fibrosis...
07:00 , Sep 9, 2002 |  BC Week In Review  |  Clinical News

DCF 987: Phase II

BCY will begin in September a Canadian Phase II trial of DCF 987 in 75 patients to treat CF. BCY LifeSciences Inc. (CDNX:BCY), Toronto, Ontario   Product: DCF 987   Business: Pulmonary   Therapeutic category:...
07:00 , Aug 12, 2002 |  BC Week In Review  |  Clinical News

DCF 987: Phase II

BCY filed a Clinical Trial Application (CTA) in Canada to begin in September a Phase II trial of DCF 987. BCY LifeSciences Inc. (CDNX:BCY), Toronto, Ontario   Product: DCF 987   Business: Pulmonary   Therapeutic...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Clinical News

BCY LifeSciences Inc. preclinical data

BCY said that treatment of respiratory epithelia cells in vitro with DCF987 reduced the number of H. influenzae bacteria that adhered to the epithelial cells. H. influenzae causes infections in patients with COPD. DCF987 is...